نشریات بند

جاری کہانی · 1 رپورٹ

FDA panel review of seven unapproved peptides

پہلی بار نشر ہوا تازہ ترین نشریہ

جاری ہےاگلی جانچ : The committee’s recommendations on whether pharmacies may compound and dispense the seven peptides.

صورتِ حال

The FDA Pharmacy Compounding Advisory Committee began its two-day review of seven unapproved peptides on July 23. FDA career scientists recommended against compounding all seven, citing a lack of human clinical data for three and inadequate data for the others; the committee’s recommendations have not yet been reported.

خبر ٹریکردن 1

1 رپورٹ11 ذرائع ابلاغ11 ماخذ1 ویڈیو

  • ابھی کوئی تاریخ والا واقعہ نہیں
    1. اپ ڈیٹ 1Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

    خبر اب تک

    1. اپ ڈیٹ 1

      Six Against the Scientists: An FDA Panel Backs Peptides With No Clinical Track Record

      A two-day meeting in Washington ended with a narrow recommendation to loosen compounding rules for unapproved compounds championed by influencers and RFK Jr. — over the objections of the agency's own staff.

      اس رپورٹ کے بعد بھی حل طلب

      • Whether the FDA will adopt the committee's recommendation in full or in part.
      • Which specific peptides failed to win a majority, given the gap between seven on the agenda and six (or four) endorsed.

    تاریخچہ

    1. شروع ہوئی1 رپورٹ

    کون شامل ہے

    افراد

    • Joe RoganAmerican broadcaster, comedian, and actor (born 1967)1 رپورٹ
    • Robert F. Kennedy Jr.26th United States Secretary of Health and Human Services since 20251 رپورٹ

    مقامات

    • ChinaChina1 رپورٹ
    • WashingtonWashington, DC, USA1 رپورٹ

    اس خبر پر ہم نے جتنے ذرائع ابلاغ پڑھے

    11 ماخذ11 ذرائع ابلاغ1 ویڈیو